Cancer Cell
Erratum

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila,[1] Robert W. Akita,[1] Kathryn Parsons,[1] Carter Fields,[1] Gail D. Lewis Phillips,[1] Lori S. Friedman,[1] Deepak Sampath,[1] and Mark X. Sliwkowski[1,*]
[1]Research Oncology, Genentech, Inc., 1 DNA Way, Mailstop 72, South San Francisco, CA 94080, USA
*Correspondence: marks@gene.com
DOI 10.1016/j.ccr.2011.12.001

(Cancer Cell *15*, 429–440; May 5, 2009)
We described experiments using the MDA-MB-361.1 cell line, which was thought to be an in vivo passaged subclone of the MDA-MB-361 cell line. The MDA-MB-361 cell line harbors *HER2* amplification and an activating *PIK3CA* mutation (E545K). Subsequent molecular profiling of the MDA-MB-361.1 cell line revealed that it is actually a derivative of the MCF7 cell line that was stably transfected to overexpress HER2 (termed MCF7-neo/HER2). MCF7 cells also harbor the activating *PIK3CA* mutation (E545K). Although the conclusions from the study are unaffected, we apologize for the discrepancy.